+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome

JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome

Human Pathology 41(5): 758-762

The 3q21q26 syndrome is recognized as a distinct clinicopathologic entity. Patients have a myeloid neoplasm associated with 3q21q26 cytogenetic abnormalities and present with anemia, leukopenia, and either thrombocytosis or a normal platelet count associated with dysplasia. To determine if JAK2 V617F mutation is implicated in the abnormal thrombopoiesis of the 3q21q26 syndrome, we analyzed bone marrow samples of 12 patients, including 10 patients with acute myeloid leukemia and 2 patients with a myelodysplastic syndrome, associated with either inv(3)(q21;q26) or t(3;3)(q21;q26). The platelet count ranged from 142 to 597 x 10(3)/microL. Using polymerase chain reaction and pyrosequencing assays, no evidence of JAK2 V617F was identified in 11 of 12 cases. A JAK2 V617F mutation was identified in one patient who had acute myeloid leukemia with concurrent mast cell disease. Separate DNA analysis of myeloblasts and mast cells after laser capture microdissection confirmed that JAK2 V617F was present in both components. We conclude that JAK2 V617F mutation is uncommon in the 3q21q26 syndrome and that its presence may indicate an unusual coexistence of a myeloproliferative neoplasm.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054022976

Download citation: RISBibTeXText

PMID: 20153505

DOI: 10.1016/j.humpath.2009.11.004

Related references

The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 92(2): 285-286, 2007

Co-occurrence of JAK2 V617F and an uncommon CALR del (p.K368fs*51) mutation facilitates JAK2/STAT signaling in polycythemia vera. Leukemia & Lymphoma 57(7): 1743-1745, 2015

Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review. Zhonghua Xue Ye Xue Za Zhi 35(12): 1122-1123, 2015

JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leukemia & Lymphoma 47(2): 313-314, 2005

JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia. British Journal of Haematology 130(6): 968-968, 2005

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1): 375-379, 2007

Evaluation of JAK2(V617F) in B and T cell neoplasms: Identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematologica (Basel) 118(4): 209-214, 2007

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106(8): 2920-2921, 2005

JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients. Journal of Gastroenterology and Hepatology 29(1): 208-214, 2014

A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F. International Journal of Laboratory Hematology 36(4): E30-E33, 2015

JAK2 V617F mutation is associated with 5q- syndrome in Chinese. Leukemia & Lymphoma 50(8): 1333-1335, 2010

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Turkish Journal of Gastroenterology 26(1): 42-48, 2015

Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to 'Hypereosinophilic syndrome: another face of janus?' by Dahabreh et al. published in Leukemia Research, in press. Leukemia Research 33(3): E1-E2, 2008

The prevalence of JAK2 V617F mutation in myelodysplastic syndrome. 2007